睿知中国医院研究地图
候选清单

正在招募淋巴瘤II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Zanubrutinib, Obinutuzumab Combined With Lenalidomide (ZGR) for the Treatment of Untreated Follicular Lymphoma

ClinicalTrials.gov 上登记的一项淋巴瘤开放试验,由中国医学科学院血液病医院(血液学研究所)牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方中国医学科学院血液病医院(血液学研究所)Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC天津医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07299149,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 7

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(7 项)收起清单
  1. 18 岁 至 90 岁;性别:不限

    登记记录的入选字段

  2. Contraception: Men and women of childbearing potential must agree to use highly effective contraception during the study and for 4 weeks after treatment discontinuation.

    入选标准第 22 条

  3. ECOG Performance Status: ≤2.

    入选标准第 13 条

  4. e) Cytopenias due to bone marrow infiltration (hemoglobin <10 g/dL, absolute neutrophil count [ANC] <1.0×10⁹/L, platelets <100×10⁹/L).

    入选标准第 9 条

    a) ANC ≥1.0×10⁹/L (without growth factor support).

    入选标准第 17 条

    b) Platelets ≥50×10⁹/L (untransfused within 7 days).

    入选标准第 18 条

    c) Total bilirubin (TBIL) ≤1.5×ULN.

    入选标准第 19 条

    d) ALT/AST ≤3×ULN.

    入选标准第 20 条

    e) Creatinine clearance ≥30 mL/min (calculated by modified Cockcroft-Gault formula).

    入选标准第 21 条

  5. Measurable Disease: At least one measurable lesion (>2 cm in longest diameter by CT/MRI).

    入选标准第 14 条

  6. Prior history of malignancy, unless the patient has been disease-free for ≥5 years and the treating physician deems the risk of recurrence low (exceptions: non-melanoma skin cancer, cured localized prostate cancer, carcinoma in situ of the cervix, or squamous intraepithelial lesions on PAP smear).

    排除标准第 5 条

    HIV, active hepatitis B/C infection (HBV DNA ≥2000 IU/mL or HCV RNA detectable)

    排除标准第 14 条

  7. Pregnancy, lactation, or unwillingness to use effective contraception in women of childbearing potential.

    排除标准第 18 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;分期或严重程度(按试验的定义)。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07299149,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Gender: No restrictions; age ≥18 years.
  2. Diagnosis: Histologically confirmed CD20-positive follicular lymphoma (FL), Grade 1, 2, or 3A, per 2016 WHO classification. All patients must provide sufficient archived or fresh tumor tissue samples for immunohistochemical (IHC) analysis.
  3. Disease Stage \& Treatment Need:
  4. Stage III or IV disease, or Stage II with bulky disease, meeting at least one of the following criteria:
  5. a) Bulky disease: Lymph node or extranodal (excluding spleen) mass with maximum diameter ≥7 cm.
  6. b) Local symptoms or organ dysfunction due to progressive lymphadenopathy or extranodal tumor mass.
  7. c) B symptoms (fever, night sweats, or unintentional weight loss >10% of body weight within ≤6 months).
  8. d) Symptomatic extranodal involvement (e.g., pleural/peritoneal effusion).
  9. e) Cytopenias due to bone marrow infiltration (hemoglobin <10 g/dL, absolute neutrophil count [ANC] <1.0×10⁹/L, platelets <100×10⁹/L).
  10. f) Involvement of ≥3 lymph nodes, each ≥3 cm in diameter.
  11. g) Symptomatic splenomegaly.
  12. Prior Therapy: No prior systemic therapy for FL.
  13. ECOG Performance Status: ≤2.
  14. Measurable Disease: At least one measurable lesion (>2 cm in longest diameter by CT/MRI).
  15. Life Expectancy: ≥6 months.
  16. Adequate Organ Function:
  17. a) ANC ≥1.0×10⁹/L (without growth factor support).
  18. b) Platelets ≥50×10⁹/L (untransfused within 7 days).
  19. c) Total bilirubin (TBIL) ≤1.5×ULN.
  20. d) ALT/AST ≤3×ULN.
  21. e) Creatinine clearance ≥30 mL/min (calculated by modified Cockcroft-Gault formula).
  22. Contraception: Men and women of childbearing potential must agree to use highly effective contraception during the study and for 4 weeks after treatment discontinuation.
  23. Informed Consent: Patients must voluntarily participate and sign informed consent forms (ICF).

排除标准:Exclusion Criteria:

  1. Patients meeting any of the following criteria will be excluded from this study:
  2. Histologic evidence of central nervous system (CNS) lymphoma, leptomeningeal lymphoma, or transformation to high-grade lymphoma (e.g., diffuse large B-cell lymphoma, DLBCL).
  3. Grade 3B follicular lymphoma (FL) or transformed FL.
  4. Ann Arbor Stage I FL.
  5. Prior history of malignancy, unless the patient has been disease-free for ≥5 years and the treating physician deems the risk of recurrence low (exceptions: non-melanoma skin cancer, cured localized prostate cancer, carcinoma in situ of the cervix, or squamous intraepithelial lesions on PAP smear).
  6. Use of any investigational drugs, antibiotics, or participation in another interventional clinical trial within 4 weeks prior to enrollment.
  7. Major surgery (excluding lymph node biopsy) within 14 days before enrollment or anticipated need for major surgery during the study.
  8. Prior treatment with zanubrutinib, obinutuzumab, or lenalidomide.
  9. Immunodeficiency or autoimmune disease history, or chronic systemic steroid therapy (>10 mg/day prednisone equivalent) or immunosuppressive therapy within 7 days before enrollment.
  10. Severe hepatic dysfunction (including severe jaundice, hepatic encephalopathy, refractory ascites, or hepatorenal syndrome), cachexia, or multi-organ failure with renal impairment.
  11. Clinically significant cardiovascular abnormalities:
  12. NYHA Class III/IV heart failure
  13. Myocardial infarction within 6 months before enrollment, Malignant arrhythmias (including QTc ≥480 ms), Uncontrolled hypertension (Systolic blood pressure (SBP) ≥150 mmHg and diastolic blood pressure (DBP) ≥100 mmHg), Unstable angina.
  14. HIV, active hepatitis B/C infection (HBV DNA ≥2000 IU/mL or HCV RNA detectable)
  15. Uncontrolled systemic infections.
  16. Bleeding disorders or coagulation abnormalities, or thrombotic events within 3 months.
  17. Severe hypersensitivity to the active ingredients or excipients of the study drugs.
  18. Pregnancy, lactation, or unwillingness to use effective contraception in women of childbearing potential.
  19. Other conditions deemed unsuitable by the investigator.

引自 ClinicalTrials.gov, NCT07299149, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07299149,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07299149